Codexis (CDXS)
Codexis Revenue Growth: 12.35%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CDXS Revenue Growth Rankings
| Overall | 64th percentile | 1548 of 4358 |
| Sector | 57th percentile | 192 of 456 in Healthcare |
| Industry | 49th percentile | 64 of 126 in Biotechnology |
CDXS Revenue Growth Range, Past 5 Years
| Minimum | 6.43% | Jun 2011 |
| Maximum | 35.15% | Sep 2010 |
| Average | 21.14% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these CDXS related companies
CDXS News
Listen to $CDXS Codexis, Inc. at Deutsche Bank Clean Tech, Utilities and Power C - live at 01:35 PM, ondemand after - http://stks.co/3puN
about 13 days ago by earningscast
about 13 days ago by earningscast
Listen to $CDXS Q1 2012 earnings call - live at 04:30 PM, ondemand after - http://stks.co/3mBW
about 17 days ago by earningscast
about 17 days ago by earningscast
Trading Radar for 05/10: Kohls (KSS), Dynegy (DYN), Express Scripts (ESRX), Molycorp (MCP) Report
May 09, 5:58PM Street Insider
May 09, 5:58PM Street Insider
$CDXS filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3aSc
about 27 days ago by MarketBrief
about 27 days ago by MarketBrief
Codexis to Announce First Quarter 2012 Financial Results on May 10, 2012
Apr 30, 4:05PM Business Wire
Apr 30, 4:05PM Business Wire
$CDXS ingredient improves yield/efficiency in process for manufacturing active pharmaceutical ingredient in $MRK diabetes drug Januvia.
about 33 days ago by abubnic
about 33 days ago by abubnic
Codexis (CDXS) Pops, Gets FDA Approval for New Stagliptin Manufacturing Process
Apr 25, 9:32AM Street Insider
Apr 25, 9:32AM Street Insider
$CDXS watching for a MOMO run today (Just FYI the chart looks great for a big run) Also all on $AAPL not selling my shares until $680(maybe)
about 33 days ago by RickPalmer907
about 33 days ago by RickPalmer907
$CDXS up 14% in AH trading after FDA Approves Use of Enzymes in $MRK Manufacturing Process http://stks.co/3UYb
about 33 days ago by abubnic
about 33 days ago by abubnic
Codexis Announces FDA Approves Use of Codexis Enzymes in Merck Manufacturing Process
Apr 24, 4:06PM Benzinga
Apr 24, 4:06PM Benzinga
$CDXS forms bearish "Symmetrical Continuation Triangle" chart pattern. http://stks.co/3LXn
about 44 days ago by RecogniaEvents
about 44 days ago by RecogniaEvents
$CDXS forms bullish "Bottom Triangle" chart pattern. http://stks.co/3JPw
about 46 days ago by RecogniaEvents
about 46 days ago by RecogniaEvents
Codexis and Merck Develop Prototype Enzyme-Based Method for Production of Boceprevir
Apr 03, 4:05PM Business Wire
Apr 03, 4:05PM Business Wire
$CDXS awarded a key patent covering important component of proprietary enzymatic technology used for production of cellulosic biofuels.
about 61 days ago by abubnic
about 61 days ago by abubnic
Codexis to Present at Sidoti’s Emerging Growth Institutional Investor Forum
Mar 13, 7:00AM Business Wire
Mar 13, 7:00AM Business Wire
Codexis Interim Chief Executive Officer to Present at Jefferies Conference
Feb 21, 8:00AM PR Newswire
Feb 21, 8:00AM PR Newswire
Bio-based earnings call: $CDXS reports 16% revenue gain in 2011. http://stks.co/2IxC
about 110 days ago by abubnic
about 110 days ago by abubnic
Ouch! $CDXS takes a whoopin' after issuing disappointing guidance for 2012; downgraded to sector perform.
about 110 days ago by abubnic
about 110 days ago by abubnic
$CDXS Reports Fourth Quarter and Full Year 2011 Results. http://stks.co/2Iwc
about 110 days ago by abubnic
about 110 days ago by abubnic
Listen to $CDXS Q4 2011 earnings call - live at 04:30 PM, ondemand after - http://stks.co/2I4X
about 110 days ago by earningscast
about 110 days ago by earningscast
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CDXS | 3.39 | +0.05 | +1.50% | 122.38M |
| CDTI | 2.63 | +0.22 | +9.13% | 18.99M |
| CCOI | 17.81 | +0.40 | +2.30% | 818.19M |
| CCO | 6.51 | -0.08 | -1.21% | 2.318B |
| CCNE | 14.82 | -0.07 | -0.47% | 184.06M |
| CCMP | 32.38 | +0.07 | +0.22% | 738.26M |
| CCM | 3.25 | -0.23 | -6.61% | 154.21M |
| CCL | 31.95 | -0.21 | -0.65% | 19.04B |
| CCK | 34.41 | +0.01 | +0.03% | 5.120B |
| CCJ | 19.17 | -0.12 | -0.62% | 7.568B |
